<DOC>
	<DOCNO>NCT02004951</DOCNO>
	<brief_summary>Over past year , endovascular intervention become important part treatment patient peripheral arterial disease.1 Indication endovascular repair femoropopliteal lesion considerably enlarge show TASC classification.1 Enlargement endovascular therapy indication base patient choice less invasive technique evidence base medicine . Consequently , TASC classification lesion modify reflect increase evidence endovascular treatment extensive femoropopliteal lesion , indication endovascular repair enlarge severe TASC type . In summary , endovascular treatment indicate TASC A B lesion correspond femoropopliteal lesion ≤15-cm . To treat lesion , interventionalists disposal huge tool box . Evaluation tool crucial determine right treatment strategy avoid reinterventions overcosts . The objective BATTLE trial compare bare metal self expandable nitinol stent ( Misago RX ) versus paclitaxel elute stent ( Zilver PTX ) treatment above-the-knee intermediate length femoropopliteal lesion . From hospital Europe ( France , Switzerland ) randomly assign patient symptomatic atherosclerotic femoropopliteal lesion treat either bare metal stent paclitaxel elute stent . In total , 186 patient randomize ( 93 per group ) .</brief_summary>
	<brief_title>BATTLE Trial : Bare Metal Stent Versus Paclitaxel Eluting Stent Setting Primary Stenting Intermediate Length Femoropopliteal Lesions</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criterion Patient ≥18 year Patient history symptomatic peripheral arterial disease ( Rutherford classification : 25 ) Lesion eligible treatment maximum 2 stent per lesion ( treatment legs permit ) Patient affiliate Social Security equivalent system Patient inform nature study , agree provision ( swiss center , sign informed consent form prior study related procedure ) Patient agree undergo protocol require followup examination requirement investigational site Reference vessel diameter 4 7mm determine CT scan ( RVD obtain average 5mm segment proximal distal lesion ) Target lesion preprocedure percent diameter stenosis ≥ 50 % DS De novo atherosclerotic lesion ( stenosis and/or occlusion ) superficial femoral artery , proximal popliteal artery ( P1 ) , . The treatment area SFA popliteal artery extend 1 cm origin profunda femoris artery 3 cm proximal margin intercondylar fossa femur . Target lesion ( single multiple ) maximal total length =14cm minimal length = 2cm At least 1 patent runoff vessel ( &lt; 50 % DS throughout course ) . The inflow artery ( y ) treat use drug elute stent drug coat balloon . Exclusion Criteria Asymptomatic lesion Restenosis No atheromatous disease Untreated &gt; 50 % DS inflow tract Resting ankle brachial index ( ABI ) unavailable Female child bear potential Patient receive , wait list major organ transplant Patient history coagulopathy refuse blood transfusion Patient receive schedule receive anticancer therapy malignancy within 1 year prior procedure Severe concomitant disease life expectation &lt; one year Known allergy paclitaxel Contraindication Aspirin Clopidogrel Ticlopidin ( patient must able receive Dual AntiPlatelet Treatment 2 month procedure ) Patient infect wound osteomyelitis ipsilateral extremity foot . Patient prior major amputation ipsilateral ( target ) extremity Patient able give inform consent ( swiss center ) Patient currently participate investigational drug device study complete primary endpoint clinically interfere current study endpoint Note : Trials require extend followup product investigational , become commercially available since , consider investigational trial Patient previously , require , bypass surgery , endarterectomy vascular surgery vessel ipsilateral extremity In Investigator 's opinion patient ( ) comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study Target lesion lie within adjacent aneurysm Patient allergy contrast agent Patient severe allergy metal Surgery endovascular intervention target member within 14 day precede BATTLE procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Superficial femoral artery</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>stent</keyword>
	<keyword>self expandable</keyword>
	<keyword>restenosis</keyword>
	<keyword>endovascular</keyword>
	<keyword>above-the-knee intermediate length</keyword>
</DOC>